Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Selling, general and administrative expenses decreased from ¥420 million in the same period of the previous year to ¥251 million. The specific factor behind the increase in net sales was Not disclosed.
A description of material events, etc. is included. Although operating losses have continued and circumstances exist that raise significant doubt about the going concern assumption, the company has secured funding for research and development through financing and believes that there is no material uncertainty regarding the going concern assumption. There are no applicable notes regarding the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥5 million (YoY +158.9%) |
| Operating profit | ¥-246 million |
| Ordinary income | ¥-244 million |
| Profit attributable to owners of the parent | ¥-238 million |
| Net income per share | △4.02 |
| Equity ratio | End of the current fiscal period 89 / End of previous period 92.2 |
| Total assets | ¥2,000 million |
| Net assets | ¥1,832 million |
| Full-year earnings forecast | Net Sales ¥507 million (YoY +296.4%) / Operating profit ¥-1,472 million / Ordinary income ¥-1,472 million / Net income ¥-1,502 million |
| Revision to Earnings Forecast | Not disclosed → Net Sales 507 / Operating profit -1,472 / Ordinary income -1,472 / Net income -1,502 |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Depreciation and amortization | ¥1,402 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥9,979 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | A description of material events, etc. is included. Although operating losses have continued and circumstances exist that raise significant doubt about the going concern assumption, the company has secured funding for research and development through financing and believes that there is no material uncertainty regarding the going concern assumption. There are no applicable notes regarding the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 0 additions, 0 exclusions (no material changes) |
| Material subsequent events | In April 2026, the company received preliminary results from the Phase 2 POC trial of Alto-101, and Alto announced a policy of not developing Alto-101 independently and instead seeking strategic partnering opportunities. In May 2026, the company entered into a legally binding term sheet with Terrain Pharmaceuticals regarding a sales partnership for Bondlido. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Event No / Subject person Not disclosed |
| Issued Shares at Period-End | 59,365,100 |
| Treasury Shares at Period-End | 2 |
| Factors Behind Changes in Business Performance | Selling, general and administrative expenses decreased from ¥420 million in the same period of the previous year to ¥251 million. The specific factor behind the increase in net sales was Not disclosed. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Selling, general and administrative expenses, including research and development expenses, decreased from ¥420 million in the same period of the previous year to ¥251 million, contributing to the narrower loss. No specific background to the increase in net sales was disclosed.